GlassScriptPhysician profile
Carlene R Springer
NPI 1669875803
$11,858.67
in general payments reported to CMS, 2019-2025
63 companies · $2,320 in 2025
The $2,320 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,921 · 2022: $2,506 · 2023: $2,888 · 2024: $2,223 · 2025: $2,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,488 · Education: $633 · Consulting Fee: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,488.31 |
| Education | $632.90 |
| Consulting Fee | $310.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $978.50 | 2021-2025 | |
| Eisai INC. | $955.72 | 2022-2025 | |
| Seagen INC. | $685.71 | 2021-2025 | Tukysa, Padcev |
| Pfizer INC. | $620.38 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $595.87 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $583.76 | 2021-2025 | Enhertu |
| Lilly USA, LLC | $453.35 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $389.96 | 2021-2023 | Imbruvica |
| Janssen Biotech, INC. | $389.83 | 2021-2025 | Rybrevant, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals LP | $374.04 | 2021-2025 | Calquence, Imfinzi, Tagrisso |
| Amgen INC. | $371.29 | 2021-2023 | Lumakras, Kyprolis, Nplate |
| Sanofi-Aventis U.S. LLC | $355.94 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $342.98 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Astellas Pharma US INC | $341.74 | 2022-2025 | Xospata, Vyloy, Padcev |
| Abbvie INC. | $331.54 | 2021-2025 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $275.22 | 2021-2025 | Jakafi, Niktimvo |
| Genzyme Corporation | $238.68 | 2021-2024 | |
| Celgene Corporation | $227.09 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Gilead Sciences, INC. | $220.03 | 2021-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $215.90 | 2021-2025 | Xpovio |
| Adaptive Biotechnologies Corporation | $212.29 | 2022-2025 | Clonoseq |
| Servier Pharmaceuticals LLC | $194.38 | 2021-2025 | |
| Exelixis INC. | $163.71 | 2022-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $159.94 | 2021-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $156.50 | 2021-2025 | Ninlaro, Iclusig, Fruzaqla |
| Tersera Therapeutics LLC | $137.69 | 2021-2025 | Zoladex |
| Genentech USA, INC. | $136.85 | 2021-2024 | Polivy, Lunsumio, Perjeta |
| Recordati_rare_diseases_inc. | $124.28 | 2025 | Enjaymo, Sylvant |
| Jazz Pharmaceuticals INC. | $124.22 | 2024-2025 | |
| Kite Pharma, INC. | $118.37 | 2021-2025 | Yescarta |
| Octapharma USA, INC. | $116.74 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Glaxosmithkline, LLC. | $109.62 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Alexion Pharmaceuticals, INC. | $98.26 | 2024-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $95.94 | 2021-2024 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $89.89 | 2022-2023 | |
| Taiho Oncology, INC. | $86.11 | 2023-2025 | |
| Pharmaessentia USA Corporation | $84.56 | 2022-2025 | Besremi |
| Array Biopharma INC | $83.59 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Syndax Pharmaceuticals, INC. | $71.95 | 2025 | |
| Mirati Therapeutics, INC. | $70.35 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $52.47 | 2023-2025 | Orserdu, Elzonris |
| Foundation Medicine, INC. | $50.10 | 2022-2023 | Foundationone Cdx |
| Tolmar Pharmaceuticals, INC. | $32.08 | 2021-2022 | |
| Tolmar, INC. | $28.60 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $28.60 | 2025 | Rubraca |
| Sobi, INC | $24.90 | 2025 | |
| Rigel Pharmaceuticals, INC. | $23.23 | 2021 | |
| Deciphera Pharmaceuticals INC. | $19.47 | 2025 | Qinlock, Romvimza |
| Novocure INC. | $19.00 | 2023 | Optune |
| Aimmune Therapeutics, INC. | $18.75 | 2025 | Zenpep |
| Clovis Oncology, INC. | $16.87 | 2022 | |
| Cti Biopharma Corp. | $16.16 | 2023 | Vonjo |
| G1 Therapeutics, INC. | $15.00 | 2023 | Cosela |
| Blueprint Medicines Corporation | $14.86 | 2021 | |
| Puma Biotechnology, INC. | $14.55 | 2021 | |
| Fennec Pharmaceuticals, INC. | $14.48 | 2025 | Fyarro |
| Medtronic, INC. | $13.09 | 2024 | Kyphon Express II Kyphopak Tray |
| Amag Pharmaceuticals, INC. | $13.05 | 2022 | |
| Blue Earth Diagnostics | $13.04 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.94 | 2022 | |
| Myriad Genetic Laboratories, INC. | $11.86 | 2021 | |
| Morphosys, US INC. | $11.55 | 2021 | |
| Iovance Biotherapeutics, INC. | $11.25 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlene Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.